We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 19

Health Canada invites public comments on new post-market reporting regulations
  • Gowling WLG
  • USA, Canada
  • August 9 2018

The medical device industry in America and perceived shortcomings in the US Food and Drug Administration's ("FDA") approval process have recently come


U.S. patients receive greater access to unapproved medications
  • Gowling WLG
  • USA
  • August 21 2009

Seriously ill patients will have greater and easier access to unapproved medicines due to new USFDA regulations.


Faster review offset by longer drug development
  • Gowling WLG
  • USA
  • January 19 2009

According to the report Outlook 2009 released by the Tufts Center for the Study of Drug Development, gains made by the U.S. FDA in the speed of review of new drugs (average review time declined by 1.1 years in time 2005-2007 period) have been largely offset by longer clinical development times due to the complexity of the diseases being studied.


Big pharma continues to woo biotech
  • Gowling WLG
  • USA
  • May 8 2008

Large pharmaceutical companies have continued their pursuit of biotech companies in 2008, maintaining a recent trend of big pharma looking to the biotech sector to find new products and technologies.


EU, US regulators ease process for orphan drugs
  • Gowling WLG
  • USA, European Union
  • December 6 2007

In an effort to encourage development of drug treatments for rare diseases, the European Commission, the European Medicines Agency and the U.S. Food and Drug Administration announced steps to streamline the application process for orphan drugs.


Scott E. Foster
  • Gowling WLG

Melissa Tehrani
  • Gowling WLG



Kieran Laird
  • Gowling WLG